AMGEN INC — Director's Dealing 2026

Mar 3, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2026-02-26

Reporting Person: Santos Esteban (EVP, Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-26	Common Stock	M	30501	$162.60	Acquired	107119	Direct
2026-02-26	Common Stock	S	30501	$379.1173	Disposed	76618	Direct
2026-02-26	Common Stock	M	24291	$177.46	Acquired	100909	Direct
2026-02-26	Common Stock	S	24291	$379.1173	Disposed	76618	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-26	Nqso (Right to Buy)	$162.60	M	30501	Disposed	2027-05-01	Common Stock (30501)	Direct
2026-02-26	Nqso (Right to Buy)	$177.46	M	24291	Disposed	2028-04-27	Common Stock (24291)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	903.8036	Indirect

Footnotes

F1: Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.

F2: The price reported is an average price of $379.1173 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer

F3: These shares include 624 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

F4: These shares are acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.